Contrast agents play a significant role in clinical MRI and are administered to detect pathology in over a third of clinical scans. Gadolinium (Gd)-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. Although GBCAs have shown efficacy and are safe to use with most patients, some GBCAs have a small risk of adverse effects, such as nephrogenic systemic fibrosis (NSF) and gadolinium deposition in the human brain. Therefore, developing novel Gd-free MRI contrast agents are in great demand. Herein, we developed a new type of MRI contrast agent using naturally derived hemin to shorten the T1 relaxation time of water.
This abstract and the presentation materials are available to members only; a login is required.